Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study - PubMed (original) (raw)
Clinical Trial
Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study
D Olivieri et al. Am J Respir Crit Care Med. 1997 Jun.
Abstract
In a double-blind, parallel-group study, we examined the effect of short-term treatment with inhaled fluticasone propionate (FP) in a group of 20 nonsmoking asthmatic patients who required only beta2-agonists to control their symptoms. We administered FP (250 microg twice daily) or matched placebo for 6 wk. Methacholine challenge was performed before treatment, after 3 wk, and at the end of treatment. Each patient underwent bronchoscopy with bronchoalveolar lavage (BAL) and bronchial biopsy before and after treatment. Eight patients in the placebo group and nine patients in the FP group completed the study. Bronchial responsiveness to methacholine decreased significantly only after 6 wk of treatment with FP (p < 0.05). When we compared the FP group with the placebo group, we observed a significant decrease only in the number of cells expressing intracellular adhesion molecule-1 (ICAM-1) and MAC-1 (p < 0.04 and p < 0.03, respectively). Moreover, we saw that the tryptase level in BAL decreased (p < 0.001), whereas the eosinophil cationic protein (ECP) level did not change significantly. Additionally, the number of eosinophils and mast cells in the lamina propria in bronchial biopsies specimens was significantly smaller in the FP group than in the placebo group (p < 0.02 and p < 0.01, respectively). Additionally, in the FP group, we found that basement-membrane thickness was significantly decreased when compared with that of the placebo group (p < 0.05). In conclusion, our results show that short-term treatment with low-dose FP reduces inflammatory cell infiltration into the lamina propria in bronchial biopsy specimens. Moreover, short-term low-dose FP treatment might control the intensity of airway remodeling in mild asthma.
Similar articles
- Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone.
Chetta A, Zanini A, Foresi A, Del Donno M, Castagnaro A, D'Ippolito R, Baraldo S, Testi R, Saetta M, Olivieri D. Chetta A, et al. Am J Respir Crit Care Med. 2003 Mar 1;167(5):751-7. doi: 10.1164/rccm.200207-710OC. Epub 2002 Dec 4. Am J Respir Crit Care Med. 2003. PMID: 12468439 Clinical Trial. - Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study.
Noonan MJ, Chervinsky P, Wolfe J, Liddle R, Kellerman DJ, Crescenzi KL. Noonan MJ, et al. J Asthma. 1998;35(2):153-64. doi: 10.3109/02770909809068203. J Asthma. 1998. PMID: 9576141 Clinical Trial. - Effect of montelukast compared with inhaled fluticasone on airway inflammation.
Overbeek SE, O'Sullivan S, Leman K, Mulder PG, Hoogsteden HC, Prins JB. Overbeek SE, et al. Clin Exp Allergy. 2004 Sep;34(9):1388-94. doi: 10.1111/j.1365-2222.2004.02041.x. Clin Exp Allergy. 2004. PMID: 15347371 Clinical Trial. - Is fluticasone propionate superior to the other available inhaled steroids?
Spahn JD. Spahn JD. J Asthma. 1998;35(4):307-11. doi: 10.3109/02770909809075664. J Asthma. 1998. PMID: 9669825 Review. No abstract available. - Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate.
Hoogsteden HC, Verhoeven GT, Lambrecht BN, Prins JB. Hoogsteden HC, et al. Clin Exp Allergy. 1999 Jun;29 Suppl 2:116-24. doi: 10.1046/j.1365-2222.1999.00020.x. Clin Exp Allergy. 1999. PMID: 10421834 Review.
Cited by
- Step one for asthma treatment: Beta2-agonists or inhaled corticosteroids?
Redington AE. Redington AE. Drugs. 2001;61(9):1231-8. doi: 10.2165/00003495-200161090-00001. Drugs. 2001. PMID: 11511019 Review. - Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.
Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB. Flood-Page P, et al. J Clin Invest. 2003 Oct;112(7):1029-36. doi: 10.1172/JCI17974. J Clin Invest. 2003. PMID: 14523040 Free PMC article. Clinical Trial. - Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma.
van der Velden VH. van der Velden VH. Mediators Inflamm. 1998;7(4):229-37. doi: 10.1080/09629359890910. Mediators Inflamm. 1998. PMID: 9792333 Free PMC article. Review. - A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Austin CD, Gonzalez Edick M, Ferrando RE, Solon M, Baca M, Mesh K, Bradding P, Gauvreau GM, Sumino K, FitzGerald JM, Israel E, Bjermer L, Bourdin A, Arron JR, Choy DF, Olsson JK, Abreu F, Howard M, Wong K, Cai F, Peng K, Putnam WS, Holweg CTJ, Matthews JG, Kraft M, Woodruff PG; CLAVIER Investigators. Austin CD, et al. Clin Exp Allergy. 2020 Dec;50(12):1342-1351. doi: 10.1111/cea.13731. Epub 2020 Oct 4. Clin Exp Allergy. 2020. PMID: 32909660 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous